EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dose‐Optimization of a Novel Co‐Formulated Triple Combination Antimalarial Therapy: Artemether‐Lumefantrine‐Amodiaquine

Joel Tarning iD, Nicholas J White iD, Arjen M Dondorp iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3582 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Joel Tarning und 2 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Amodiaquine, Antimalarials, Artemether, Lumefantrine Drug Combination, Malaria, Falciparum. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artemisinin‐based combination therapy (ACT) is the first‐line therapy for uncomplicated falciparum malaria, but artemisinin resistance in Asia and now sub‐Saharan Africa is threatening our ability to control and eliminate malaria. Triple‐ACTs have emerged as a viable alternative treatment to combat declining ACT efficacy due to drug‐resistant malaria. In this study, we developed and evaluated an optimal fixed‐dose regimen of artemether‐lumefantrine‐amodiaquine through population pharmacokinetic modeling and simulation. Three published population‐based pharmacometric models and two large cohorts of observed adult subjects and pediatric malaria patients were used to simulate pharmacokinetic profiles of different dosing strategies. Based on simulated total exposure and peak concentrations, an optimal dose regimen was developed resulting in an extension of the current 4 weight bands to a total of 5 weight bands to generate equivalent exposures in all body weight groups and minimize the fluctuation in exposure between patients. The proposed drug‐to‐drug ratio of artemether‐lumefantrine‐amodiaquine (20:120:40 mg) was kept constant throughout the dosing bands in order to simplify manufacturing, implementation, and further development of a fixed‐dose co‐formulated product.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationMalaria, FalciparumFluorenesHumansChildAdultDrug CombinationsMaleChild, PreschoolFemaleModels, BiologicalAdolescentDose-Response Relationship, DrugDrug Therapy, CombinationYoung AdultArtemisininsComputer Simulation

Substanzen

AmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationDrug CombinationsArtemisininsFluorenes

Autor:innen und Institutionen

  • Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

ORCID-Profile: Joel Tarning, Nicholas J White, Arjen M Dondorp

Förderung

  • Wellcome Trust

Zitieren

APA

Tarning, J., White, N. J., & Dondorp, A. M. (2025). Dose‐Optimization of a Novel Co‐Formulated Triple Combination Antimalarial Therapy: Artemether‐Lumefantrine‐Amodiaquine. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3582

Vancouver

Tarning J, White NJ, Dondorp AM. Dose‐Optimization of a Novel Co‐Formulated Triple Combination Antimalarial Therapy: Artemether‐Lumefantrine‐Amodiaquine. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3582

BibTeX
@article{Tarning2025,
  author = {Tarning, Joel and White, Nicholas J and Dondorp, Arjen M},
  title = {Dose‐Optimization of a Novel Co‐Formulated Triple Combination Antimalarial Therapy: Artemether‐Lumefantrine‐Amodiaquine},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3582}
}
Kostenlos starten →